摘要
目的:探讨丙谷胺(PGM)抑制胃癌BGC-823细胞增殖及胃泌素的促增殖作用,通过P16及P21蛋白表达的变化,为内分泌途径治疗胃癌提供理论依据,并提供内分泌途径治疗癌症疗效的指标。方法:通过体外细胞培养及对癌细胞进行分组实验研究,应用免疫荧光技术及Northern blot方法测定癌细胞内P16及P21蛋白的表达情况。结果:P16蛋白的表达量随PGM的抑癌作用而升高,两者呈负相关;P21蛋白的表达量与PGM的抑癌作用无明显相关。结论:丙谷胺作为胃癌的一种内分泌治疗手段,可采用P16的表达情况作为其疗效的一个指标。
Objective: To explore the effect of proglumide (PGM) on inhibiting the multiplication of stomach cancer cell line BGC-823 and the effect of gastrin on multiplication of BGC-823, and provide theoretical basis for curing stomach cancer for endocrine pathway by the expression change of P16 and P21, and provide indicators for the cure effect of endocrine pathway. Methods: Stomach cancer cells were cultured in vitro and divided into different groups for experiment, then immunofluorescent technique and Northern blot were used to detect the expression of P16 and P21. Results: The expression of P16 protein increased with the inhibitory effect of PGM, and they showed negative correlation; the expression of P21 protein showed no obvious correlation with the inhibitory effect of PGM. Conclusion: As one of the endocrine cure methods for stomach cancer, the expression of P16 can be one indicator for the curative effect.
出处
《中国医药导报》
CAS
2009年第32期5-7,共3页
China Medical Herald